Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Izaskun Gabari"'
Autor:
Alicia Aranguren, Esther Larrea, Ignacio Melero, Asis Palazon, Juan Dubrot, Uxua Mancheño, José-Ignacio Riezu-Boj, Izaskun Gabari, Jesús Prieto, Iranzu González, Sandra Hervas-Stubbs, Juan Carlos Ruiz, Arantza Azpilicueta
Publikováno v:
European Journal of Immunology. 40:3389-3402
IFN-α/β link innate and adaptive immune responses by directly acting on naïve CD8(+) T cells. This concept unveiled in mice remains unexplored in humans. To investigate that, human CD8(+) CD45RO(-) cells were stimulated with beads coated with anti
Autor:
Sarai Solano, Arantza Azpilikueta, Carmen Berasain, Asis Palazon, Carlos Alfaro, Oihana Murillo, Pedro Berraondo, Ignacio Melero, Ainhoa Arina, Maria C. Ochoa, Jose Luis Perez-Gracia, Juan Dubrot, Sandra Hervas-Stubbs, Izaskun Gabari
Publikováno v:
European Journal of Immunology. 39:2424-2436
Anti-CD137 mAb are capable of inducing tumor rejection in several syngeneic murine tumor models and are undergoing clinical trials for cancer. The anti-tumor effect involves co-stimulation of tumor-specific CD8(+) T cells. Whether antigen cross-prese
Autor:
Carmen Berasain, Arantza Azpilikueta, Silvano Ferrini, Carlos Alfaro, Sandra Hervas-Stubbs, Oihana Murillo, Jesús Prieto, Juan Dubrot, Ignacio Melero, Ainhoa Arina, Jose Luis Perez-Gracia, Izaskun Gabari
The surface phenotype CD3-NK1.1+DX5+CD11c(int)B220+GR1- has been recently ascribed to a novel subset of mouse leukocytes termed interferon (IFN)-producing killer dendritic cells (IKDCs) that shares functions with natural killer (NK) cells and DCs. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad1290a50fd578d0be120776dc4684ff
https://hdl.handle.net/10171/20370
https://hdl.handle.net/10171/20370
Autor:
Ignacio, Melero, Izaskun, Gabari, Iñigo, Tirapu, Ainhoa, Arina, Guillermo, Mazzolini, Elena, Baixeras, Esperanza, Feijoo, Carlos, Alfaro, Cheng, Qian, Jesús, Prieto
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(10 Pt 1)
Systemic treatment with an anti-ICAM-2 monoclonal antibody (mAb; EOL4G8) eradicates certain established mouse tumors through a mechanism dependent on the potentiation of a CTL-mediated response. However, well-established tumors derived from the MC38
Autor:
Ignacio, Melero, Izaskun, Gabari, Angel L, Corbí, Miguel, Relloso, Guillermo, Mazzolini, Volker, Schmitz, Mercedes, Rodriguez-Calvillo, Iñigo, Tirapu, Emilio, Camafeita, Juan P, Albar, Jesús, Prieto
Publikováno v:
Cancer research. 62(11)
Monoclonal antibodies (mAbs) can mediate antitumor effects by indirect mechanisms involving antiangiogenesis and up-regulation of the cellular immune response rather than by direct tumor cell destruction. From mAbs raised by immunization of rats with
Autor:
Iñigo, Tirapu, Guillermo, Mazzolini, Mercedes, Rodriguez-Calvillo, Ainhoa, Arina, Belen, Palencia, Izaskun, Gabari, Ignacio, Melero
Publikováno v:
Archivum immunologiae et therapiae experimentalis. 50(1)
Cellular immune responses can destroy cancer cells, achieving the cure of experimental malignancies. An expanding wealth of knowledge on the molecular basis of how to prime and amplify a T cell response has fueled a number of strategies successful at
Autor:
Oihana Murillo, Ignacio Melero, Jose Luis Perez Gracia, Carlos Alfaro, Sandra Hervas-Stubbs, Izaskun Gabari, Ainhoa Arina, Juan Dubrot, Carmen Berasain, Jesús Prieto, Silvano Ferrini, Arantza Azpilikueta
Publikováno v:
Cytokine. 39:29